SG
UTHR icon

Sankala Group’s United Therapeutics UTHR Stock Holding History

Sankala Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.17K Sell
10
-16
-62% -$9.01K ﹤0.01% 460
2026
Q1 		$13.9K Hold
26
– – 0.01% 342
2025
Q4 		$13.1K Buy
+26
New +$12.1K 0.01% 353

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Sankala Group's UTHR Position: Q2 2026 in Review

Sankala Group reduced its United Therapeutics (UTHR) stake by 62% in Q2 2026, selling an estimated $9.01K and leaving 10 shares worth $5.17K. The position accounts for ﹤0.01% of the portfolio, ranked #460.

Sankala Group first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $13.9K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Sankala Group held 10 shares of United Therapeutics worth $5.17K as of Q2 2026.
  • Sankala Group sold 16 United Therapeutics shares in Q2 2026, an estimated $9.01K.
  • United Therapeutics made up ﹤0.01% of Sankala Group's portfolio in Q2 2026, its #460 holding.
  • Sankala Group first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Sankala Group's United Therapeutics position peaked at $13.9K in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.